Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Scientific Reports|January 10, 2024
Predicting treatment outcomes of intravitreal brolucizumab for polypoidal choroidal vasculopathy through noninvasive assessment of polypoidal lesion blood flow with optical coherence tomography angiographyJunki Hoshino, Hidetaka Matsumoto, Kosuke Nakamura, et al.
Japanese Journal of Ophthalmology|January 20, 2024
One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degenerationHidetaka Matsumoto, Junki Hoshino, Kosuke Nakamura, et al.
Japanese Journal of Ophthalmology|January 23, 2025
Efficacy of switching to brolucizumab for neovascular age-related macular degeneration refractory to faricimabJunki Hoshino, Hidetaka Matsumoto, Kosuke Nakamura, et al.
Scientific Reports|February 24, 2023
Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularizationHidetaka Matsumoto, Junki Hoshino, Kosuke Nakamura, et al.
Scientific Reports|March 25, 2021
Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathyHidetaka Matsumoto, Junki Hoshino, Ryo Mukai, et al.
Japanese Journal of Ophthalmology|May 19, 2026
One-year outcomes of treat-and-extend regimen with intravitreal aflibercept 8 mg for treatment-naïve neovascular age-related macular degenerationHidetaka Matsumoto, Junki Hoshino, Saki Numaga, et al.
Japanese Journal of Ophthalmology|July 10, 2025
Loading phase outcomes of intravitreal aflibercept 8 mg for treatment-naïve neovascular age-related macular degenerationHidetaka Matsumoto, Junki Hoshino, Saki Numaga, et al.
Japanese Journal of Ophthalmology|November 10, 2025
Two-year outcomes of half-fluence photodynamic therapy combined with intravitreal aflibercept for treatment-naïve pachychoroid neovasculopathyJunki Hoshino, Hidetaka Matsumoto, Saki Numaga, et al.
Scientific Reports|May 17, 2022
One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularizationHidetaka Matsumoto, Junki Hoshino, Ryo Mukai, et al.
Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde|July 14, 2022
Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term OutcomesJunki Hoshino, Hidetaka Matsumoto, Ryo Mukai, et al.
Pageof 3